Ashland biomanfacturer partners with Japanese firm
Ashland bioactive nanotechnology manufacturing company BioSurfaces is partnering with Takeda Pharmaceutical of Japan on developing medical devices to treat patients with gastrointestinal diseases.
The partnership, announced Tuesday, has Takeda and BioSurfaces exploring therapeutic approaches for treating gastrointestinal issues. Takeda will provide scientific and technical expertise in gastroenterology, while BioSurfaces will provide medical device design and nanomaterial expertise and fabrication technology.
BioSurfaces specializes in producing nanofibrous materials out of polymers approved by the U.S. Food & Drug Administration to be used to form a variety of difficult-to-manufacture shapes while also improving biocompatibility over other textile-based medical implants.
Those materials promote quicker and more thorough healing by fully integrating with the body’s tissue, BioSurfaces said in a statement.
The company’s manufacturing process allows drugs or other bioactive agents to be directly incorporated into nanofibers for localized release.
Both companies said they hope the collaboration will lead to the cutting-edge use of biopolymers and device fabrication technology to help prevent strictures and promote healing of fistulas, which are common manifestations of gastrointestinal diseases.
Additional terms of the agreement, including financials, were not disclosed.
WBJ Web Partners
Most Recent
Most Recent
0 Comments